Merck and Eisai tease results for renal carcinoma treatment

Eisai and Merck & Co Inc (MSD) will present data at the American Society of Clinical Oncology (ASCO) meeting from their Phase III trial for the combination therapy of Lenvima plus Keytruda as a first-line treatment for advanced renal cell carcinoma (RCC).